Yuga Komaki1, Fukiko Komaki1, Dejan Micic2, Akio Ido3, Atsushi Sakuraba1. 1. Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, The University of Chicago Medicine, Chicago, Illinois, USA. 2. Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 3. Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Abstract
BACKGROUND AND AIMS: The risk of colorectal cancer (CRC) in various chronic liver diseases compared with the general population remains unclear. We performed a systematic review and meta-analysis to assess the risk of CRC in patients with chronic liver diseases before and after liver transplantation. METHODS: Electronic databases were searched for studies assessing the risk of CRC in patients with chronic liver diseases. The primary outcome was the pooled risk of CRC among studies that reported the risk as standardized incidence rate (SIR). RESULTS: Fifty studies that included 55,991 patients were identified. Among studies that included hepatitis and cirrhotic patients, the pooled SIR was 2.06 (P < .0001; 95% confidence interval (CI), 1.46-2.90) with moderate heterogeneity (I2 = 49.2%), which appeared to be because of the difference between subgroup of diseases and the power of studies. Three studies reported an increased risk of CRC in primary sclerosing cholangitis patients (pooled SIR 6.70; P < .0001; 95% CI, 3.48-12.91) with moderate heterogeneity (I2 = 36.3%), which appeared to be because of the difference between the power of studies. Among studies that included post-transplant patients, the pooled SIR was 2.16 (P < .0001; 95% CI, 1.59-2.94) with moderate heterogeneity (I2 = 56.4%). Meta-regression showed a correlation between the proportion of autoimmune-related liver diseases and the risk of CRC. CONCLUSIONS: Patients with chronic liver diseases had an increased risk of CRC compared with the general population, which persisted after liver transplantation. A more intensive surveillance for CRC is warranted in this population.
BACKGROUND AND AIMS: The risk of colorectal cancer (CRC) in various chronic liver diseases compared with the general population remains unclear. We performed a systematic review and meta-analysis to assess the risk of CRC in patients with chronic liver diseases before and after liver transplantation. METHODS: Electronic databases were searched for studies assessing the risk of CRC in patients with chronic liver diseases. The primary outcome was the pooled risk of CRC among studies that reported the risk as standardized incidence rate (SIR). RESULTS: Fifty studies that included 55,991 patients were identified. Among studies that included hepatitis and cirrhoticpatients, the pooled SIR was 2.06 (P < .0001; 95% confidence interval (CI), 1.46-2.90) with moderate heterogeneity (I2 = 49.2%), which appeared to be because of the difference between subgroup of diseases and the power of studies. Three studies reported an increased risk of CRC in primary sclerosing cholangitispatients (pooled SIR 6.70; P < .0001; 95% CI, 3.48-12.91) with moderate heterogeneity (I2 = 36.3%), which appeared to be because of the difference between the power of studies. Among studies that included post-transplant patients, the pooled SIR was 2.16 (P < .0001; 95% CI, 1.59-2.94) with moderate heterogeneity (I2 = 56.4%). Meta-regression showed a correlation between the proportion of autoimmune-related liver diseases and the risk of CRC. CONCLUSIONS:Patients with chronic liver diseases had an increased risk of CRC compared with the general population, which persisted after liver transplantation. A more intensive surveillance for CRC is warranted in this population.
Authors: Kristina M Jordahl; Anna Shcherbina; Andre E Kim; Yu-Ru Su; Yi Lin; Jun Wang; Conghui Qu; Demetrius Albanes; Volker Arndt; James W Baurley; Sonja I Berndt; Stephanie A Bien; D Timothy Bishop; Emmanouil Bouras; Hermann Brenner; Daniel D Buchanan; Arif Budiarto; Peter T Campbell; Robert Carreras-Torres; Graham Casey; Tjeng Wawan Cenggoro; Andrew T Chan; David V Conti; Christopher H Dampier; Matthew A Devall; Virginia Díez-Obrero; Niki Dimou; David A Drew; Jane C Figueiredo; Steven Gallinger; Graham G Giles; Stephen B Gruber; Andrea Gsur; Marc J Gunter; Heather Hampel; Sophia Harlid; Tabitha A Harrison; Akihisa Hidaka; Michael Hoffmeister; Jeroen R Huyghe; Mark A Jenkins; Amit D Joshi; Temitope O Keku; Susanna C Larsson; Loic Le Marchand; Juan Pablo Lewinger; Li Li; Bharuno Mahesworo; Victor Moreno; John L Morrison; Neil Murphy; Hongmei Nan; Rami Nassir; Polly A Newcomb; Mireia Obón-Santacana; Shuji Ogino; Jennifer Ose; Rish K Pai; Julie R Palmer; Nikos Papadimitriou; Bens Pardamean; Anita R Peoples; Paul D P Pharoah; Elizabeth A Platz; John D Potter; Ross L Prentice; Gad Rennert; Edward Ruiz-Narvaez; Lori C Sakoda; Peter C Scacheri; Stephanie L Schmit; Robert E Schoen; Martha L Slattery; Mariana C Stern; Catherine M Tangen; Stephen N Thibodeau; Duncan C Thomas; Yu Tian; Konstantinos K Tsilidis; Cornelia M Ulrich; Franzel J B van Duijnhoven; Bethany Van Guelpen; Kala Visvanathan; Pavel Vodicka; Emily White; Alicja Wolk; Michael O Woods; Anna H Wu; Natalia Zemlianskaia; Jenny Chang-Claude; W James Gauderman; Li Hsu; Anshul Kundaje; Ulrike Peters Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-05-04 Impact factor: 4.090
Authors: Victor Chun-Lam Wong; Ming-In Wong; Chi-Tat Lam; Maria Li Lung; Ka-On Lam; Victor Ho-Fun Lee Journal: J Cancer Date: 2021-06-01 Impact factor: 4.207
Authors: Preeti Kanikarla Marie; Natalie W Fowlkes; Vahid Afshar-Kharghan; Stephanie L Martch; Alexey Sorokin; John Paul Shen; Van K Morris; Arvind Dasari; Nancy You; Anil K Sood; Michael J Overman; Scott Kopetz; David George Menter Journal: Front Oncol Date: 2021-07-21 Impact factor: 6.244